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COMMENTARY
Combating Parkinson’s disease-associated toxicity
by modulating proteostasis
Yangshin Parka,b,c and Quyen Q. Hoanga,b,c,1
The incidence of age-associated neurodegenerative
disease is growing rapidly, and it is expected to triple
by 2050 (1). Currently, there are no cures or treatments
that significantly modify disease progression. As re-
searchers develop an in-depth understanding of the
mechanisms of neurodegeneration, common features
across different diseases are becoming apparent.
Chief among them is the presence of protein aggre-
gates, such as amyloid plaques and tau tangles in Alz-
heimer’s disease (2); α-synuclein–rich Lewy bodies and
Lewy neurites in Parkinson’s disease (3); huntingtin
aggregates in Huntington’s disease (4); and aggre-
gates of superoxide dismutase 1 (SOD1), TDP43, and
FUS in amyotrophic lateral sclerosis (5). Although the
precise mechanisms of protein aggregation-associated
toxicity remain unclear, the accumulation of aggregated
proteins in the diseased neurons indicates imbalances
in protein homeostasis (proteostasis) (proteostasis is re-
viewed in ref. 6). As such, researchers are studying the
potential therapeutic strategy of restoring proteostasis
to normal levels by boosting the activity of molecular
chaperones. One way to do so is to activate HSF1 (heat
shock factor protein 1) by inhibiting HSP90 (heat shock
protein 90), thereby stimulating the expression of multi-
ple chaperones. Indeed, this strategy has been shown to
be effective in fly models of Parkinson’s disease and
Huntington’s disease (7, 8). However, toxicity associated
with HSP90 inhibition remains an ongoing concern. An
alternative potential strategy recently proposed is to ac-
tivate the stress-inducible genes by activating the tran-
scription activator nuclear factor erythroid 2-related
factor (Nrf2) (9). Nrf2 controls the expression of multiple
stress-inducible genes in response to oxidative stress
(10, 11), proteostasis (12, 13), and inflammation (14). It
does so by binding to the upstream regulatory DNA
sequence known as the antioxidant response element.
In PNAS, Skibinski et al. (15) investigate the effects of
Nrf2 activation on cellular toxicity induced by two different
Parkinson’s disease-associated proteins, α-synuclein and
leucine-rich repeat kinase 2 (LRRK2).
Parkinson’s disease is a common neurodegenera-
tive disease that is characterized by progressive
neuronal loss in the substantia nigra pars compacta.
Although the precise mechanism of neuronal death
remains unknown, genetic studies in the past two de-
cades have identified a number of genes associated
with rare inheritable Parkinson’s disease, including
Parkin/PRKN, DJ-1/Park7, PINK1, SNCA (α-synuclein),
and LRRK2 (16). α-Synuclein is a small protein (140
residues) whose mutation is associated with disease
pathogenesis, and it is the main protein found in Lewy
bodies of Parkinson’s disease brains (16). Although
the mechanism of α-synuclein–associated toxicity is
still unclear, it has been shown that its disease-asso-
ciated mutants are aggregation-prone and its aggre-
gates are associated with neuronal toxicity (17, 18).
LRRK2 is a large (2,527 amino acids) multidomain
protein whose mutation is a common cause of Par-
kinson’s disease (19). The mechanism by which
LRRK2 causes Parkinson’s disease remains unclear;
however, the disease-associated LRRK2 mutants
have been shown to display aberrant GTPase and
kinase activities (20, 21).
Fig. 1. Cartoon presentation of Nrf2 rescuing LRRK2-
and α-synuclein (α-Syn)–induced toxicity as described by
Skibinski et al. (15). Nrf2 activation leading to the
transcription of stress-inducible genes resulted in a
reduction of toxic levels of α-synuclein and sequestration
of toxic LRRK2 mutants into inclusion bodies.
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To investigate the effects of Nrf2 activation on α-synuclein–
and LRRK2-induced toxicity, Skibinski et al. (15) created expres-
sion constructs of α-synuclein and LRRK2 fused with differently
colored fluorescent proteins and cotransfected each with an
Nrf2 expression vector into neurons. The same set of transfected
neurons was observed over a period of 1 wk, and images were
taken at 12- to 24-h intervals using a robotic automated micro-
scope the authors built (22). Using this imaging assay system,
Skibinski et al. (15) first confirmed that Nrf2 was functional in the
cells they used and then that the expression of α-synuclein and
LRRK2 mutants was indeed toxic, thereby confirming the fidelity
of the assay to be used.
In rat neurons cotransfected with Nrf2 and α-synuclein expres-
sion vectors, Skibinski et al. (15) observed that the activation of
Nrf2 rescued α-synuclein–induced toxicity. Similarly, activation of
Nrf2 also rescued rat neurons expressing two different disease-
associated mutants of LRRK2, G2019S and Y1669C. To determine
whether these rescue effects of Nrf2 also occur in human neurons,
Skibinski et al. (15) repeated the same experiments using human
induced pluripotent stem cell-derived neurons, in which they ob-
served similar rescue effects for α-synuclein–induced toxicity.
To gain insights into the mechanism of Nrf2 rescue, Skibinski
et al. (15) transfected neurons with α-synuclein fused to a green-
Dendra2 fluorescence protein and quantified the green fluores-
cence level in the presence and absence of Nrf2 expression. The
fluorescence levels in neurons expressing Nrf2 were found to be
lower than the levels of controls, thus suggesting that Nrf2 acti-
vation might modulate α-synuclein turnover. Using an elegant
method called optical pulse labeling (which irreversibly turns
green Dendra2–α-synuclein red) to determine the lifetime of Den-
dra2–α-synuclein in neurons, Skibinski et al. (15) observed that
activation of Nrf2 resulted in about a 10% increase in the rate of
Dendra2–α-synuclein clearance compared with controls, thus sug-
gesting that Nrf2 rescued α-synuclein–induced toxicity by lower-
ing the cellular steady-state levels of α-synuclein (Fig. 1).
Skibinski et al. (15) used the same optical pulse labeling ex-
periment to examine the neurons expressing toxic mutants of
LRRK2. Interestingly, they found no reduction in steady-state lev-
els of LRRK2 upon Nrf2 activation. Instead, they observed that
Nrf2 activation led to a significantly greater risk of inclusion body
formation for the Parkinson’s disease-associated LRRK2 mutants,
thus suggesting that Nrf2 activation might reduce LRRK2-associ-
ated toxicity by sequestering its toxic forms into potentially more
inert inclusion bodies (Fig. 1).
It remains to be determined whether Nrf2 activation is an
effective strategy for treating Parkinson’s disease and its potential
application for other neurodegenerative diseases; however, given
the increasingly broad function of Nrf2 in different stress response
pathways, proteostasis, and immunity, it offers an exciting addi-
tion to the arsenal for combating neurodegeneration.
1 Prince M, et al. (2015) The global impact of dementia. World Alzheimer Report 2015 (Alzheimer’s Disease International, London), pp 1–82.
2 Krstic D, Knuesel I (2013) Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 9(1):25–34.
3 Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454.
4 Labbadia J, Morimoto RI (2013) Huntington’s disease: Underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38(8):378–385.
5 Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14(4):248–264.
6 Labbadia J, Morimoto RI (2015) The biology of proteostasis in aging and disease. Annu Rev Biochem 84:435–464.
7 Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease.
Science 295(5556):865–868.
8 Fujikake N, et al. (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of
multiple molecular chaperones. J Biol Chem 283(38):26188–26197.
9 Esteras N, Dinkova-Kostova AT, Abramov AY (2016) Nrf2 activation in the treatment of neurodegenerative diseases: A focus on its role in mitochondrial
bioenergetics and function. Biol Chem 397(5):383–400.
10 Ishii T, et al. (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275(21):
16023–16029.
11 Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J (2016) Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An
evolutionarily conserved mechanism. Cell Mol Life Sci 73(17):3221–3247.
12 Kwak MK, et al. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene
clusters for cell survival. J Biol Chem 278(10):8135–8145.
13 Tsvetkov AS, et al. (2013) Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol 9(9):586–592.
14 Ahmed SM, Luo L, Namani A, Wang XJ, Tang X (2016) Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta 1863(2):585–597.
15 Skibinski G, et al. (2017) Nrf2 mitigates LRRK2- and α-synuclein–induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci USA 114:1165–1170.
16 Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) Genetics of Parkinson’s disease and parkinsonism. Ann Neurol 60(4):389–398.
17 Wang W, et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108(43):17797–17802.
18 Wang W, et al. (2016) Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein. Proc Natl Acad Sci USA 113(34):
9587–9592.
19 Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci 11(12):791–797.
20 Greggio E, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23(2):329–341.
21 Liao J, et al. (2014) Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domain. Proc Natl Acad Sci USA 111(11):
4055–4060.
22 Arrasate M, Finkbeiner S (2005) Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci USA 102(10):3840–3845.
804 | www.pnas.org/cgi/doi/10.1073/pnas.1620082114 Park and Hoang
